pharmaceuticals - Publications - Faculty & Research

Web

All Industries

Entertainment / Media 3% $150k 25th Percentile Base $165k Median $184k 75th Percentile Base $13k 40% Receiving $21k 60% Receiving Health Care 6% + – Expand Row $145k 25th Percentile Base $165k Median $185k 75th Percentile Base $30k 66% Receiving $29k 71% Receiving... View Details

Debora L. Spar

Debora Spar is the Jaime and Josefina Chua Tiampo Professor of Business Administration at Harvard Business School and Senior Associate Dean for Business and Global Society. Her current research focuses on issues of gender and technology, and the interplay between... View Details

Keywords: pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals

Web

Employment Data Trends

Employment Data Trends Employment Data Trends Trends Career Data Internship Data Trends by Industry 2020 2021 2022 2023 2024 Consulting 24% 23% 26% 25% 18% Consumer Products 3% 3% 3% 4% 3% Entertainment / Media 2% 3% 3% 1% 3% Health Care 7% 6% 5% 5% 6% Biomed / View Details

09 Feb 2024
HBS Case

Slim Chance: Drugs Will Reshape the Weight Loss Industry, But Habit Change Might Be Elusive

Year after year, millions of people make a new year’s resolution to lose weight. But because success traditionally depends on making major lifestyle changes, like eating healthier and exercising more, many people fall short of their fitness goals. Yet in 2024, more... View Details

Keywords: by Lane Lambert; Pharmaceutical; Pharmaceutical

18 Apr 2023
Research & Ideas

The Best Person to Lead Your Company Doesn't Work There—Yet

within their own ranks. “What you really do need is knowledge of that specific industry, whether it's pharmaceutical or manufacturing or hospitality or rocket science.” The findings suggest an active market for CEOs, who are lured to... View Details

Keywords: by Rachel Layne; Financial Services

Rosabeth M. Kanter

Rosabeth Moss Kanter holds the Ernest L. Arbuckle Professorship at Harvard Business School, specializing in strategy, innovation, and leadership for change. Her strategic and practical insights guide leaders worldwide through teaching, writing, and direct... View Details

Gary P. Pisano

Gary Pisano is the Harry E. Figgie, Jr. Professor of Business Administration at the Harvard Business School where he has been on the faculty since 1988. From 2018-2023, Pisano was Harvard Business School’s Senior Associate Dean for Faculty Promotion and... View Details

Keywords: pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals

Youngme Moon

Youngme Moon is the Donald K. David Professor of Business at Harvard Business School. Professor Moon's research sits at the intersection of brand strategy and culture, with a particular focus on the emergent AI economy. She is the author of the bestselling book, View Details

Kyle R. Myers

Kyle Myers is an associate professor of business administration in the Technology and Operations Management unit. He teaches the first-year Technology and Operations Management course.

Professor Myers studies the economics of innovation. His research is at... View Details

Keywords: pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals

January–February 2023
Article

Forecasting COVID-19 and Analyzing the Effect of Government Interventions

By: Michael Lingzhi Li, Hamza Tazi Bouardi, Omar Skali Lami, Thomas Trikalinos, Nikolaos Trichakis and Dimitris Bertsimas

We developed DELPHI, a novel epidemiological model for predicting detected cases and deaths in the prevaccination era of the COVID-19 pandemic. The model allows for underdetection of infections and effects of government interventions. We have applied DELPHI across more... View Details

Keywords: COVID-19 Pandemic; Epidemics; Analytics and Data Science; Health Pandemics; AI and Machine Learning; Forecasting and Prediction

Citation

Read Now

Web

HBS - The year in Review

standards, and values of the School. The recipients were honored during the Class Day ceremony. The 2023 Award recipients were Reshma Kewalramani MD, FASN (GMP 18, 2015) CEO and President, Vertex Pharmaceuticals Depelsha Thomas McGruder... View Details

October 1982 (Revised May 1992)
Case

Johnson & Johnson: The Tylenol Tragedy

By: Stephen A. Greyser

In October 1982, Johnson & Johnson was confronted with a major crisis when seven deaths were attributed to poisoned Tylenol. The case reviews the facts as known a week after the incident occurred, and raises a wide range of questions regarding consumer behavior,... View Details

Keywords: Consumer Behavior; Corporate Social Responsibility and Impact; Competitive Strategy; Crisis Management; Health Care and Treatment; Pharmaceutical Industry

Citation

Educators

Purchase

Research Summary

Clinical Trials as a setting for Health Policy and Management Research

The clinical trial marketplace is in flux. A decade ago, pharmaceutical firms almost exclusively conducted the study of their novel drug compounds within major academic medical centers. But today, industry-sponsored clinical trials are increasingly using community... View Details

13 Jul 2020
Research & Ideas

Merck CEO Ken Frazier Discusses a COVID Cure, Racism, and Why Leaders Need to Walk the Talk

As chairman and CEO of the leading vaccine producer in the world, pharmaceutical giant Merck & Co., Ken Frazier has one of the highest-profile positions in global business. But Frazier, who is leading one of the firms on a charge to... View Details

Keywords: by Staff; Pharmaceutical

15 Jan 2019
First Look

New Research and Ideas, January 15, 2019

December 19, 2018 NEJM Catalyst It's Time to Reform the Orphan Drug Act By: Bagley, Nicholas, Amitabh Chandra, Craig Garthwaite, and Ariel Dora Stern Abstract—No abstract available. Publisher's link: https://www.hbs.edu/faculty/Pages/item.aspx?num=55448 January 2019... View Details

Keywords: Dina Gerdeman

Research Summary

Regulatory Change/Business-Government Relations

“Sources of Learning Heterogeneity: Discontinuous Regulatory Shock and its Impact on Organizational Search Behaviors”

Co-authoring with Jerry Kim, in this study I look at how discontinuous regulatory shock shapes organizational... View Details

Keywords: Business ＆ Government Relations; Regulations; Regulatory Capture; Pharmaceutical Industry; United States

November–December 2015
Article

Active Postmarketing Drug Surveillance for Multiple Adverse Events

By: Joel Goh, Margrét V. Bjarnadóttir, Mohsen Bayati and Stefanos A. Zenios

Postmarketing drug surveillance is the process of monitoring the adverse events of pharmaceutical or medical devices after they are approved by the appropriate regulatory authorities. Historically, such surveillance was based on voluntary reports by medical... View Details

Keywords: Drug Surveillance; Health Care; Stochastic Models; Queueing; Diffusion Approximation; Brownian Motion; Health Care and Treatment; Analytics and Data Science; Analysis

Citation

Find at Harvard

Portrait Project

Albert Chiu

continue to inspire me. I want to reshape how vaccines and pharmaceuticals are manufactured and bring these life-saving products to patients more quickly and cheaply. From SARS to COVID-19 and beyond, I want to use my skills and education... View Details

William A. Sahlman

William Sahlman is a Baker Foundation Professor of Business Administration at Harvard Business School.

Mr. Sahlman received an A.B. degree in Economics from Princeton University (1972), an M.B.A. from Harvard University (1975), and a Ph.D. in Business... View Details

Forthcoming
Article

Achieving Epilepsy Care for All: Ecosystem-Based Transformation

By: Susanna Gallani, Bernice Martin Lee and Lidia M. V. R. Moura

Epilepsy exemplifies many of the systemic challenges of modern health care— fragmented care delivery, inequitable access, financial strain, and so on. The current “system of systems” (SoS) structure of U.S. health care fosters siloed operations among its member systems... View Details

Keywords: Healthcare Delivery; Epilepsy; Seizures; Health Care and Treatment; Health Disorders; Equality and Inequality; Framework; Service Delivery